Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | AR | P10275 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KLK1 | P06870 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclofenil SCHEMBL11222765 | 0.89 | ESR1 (1.00) | ESR1PGRCHRM2ADORA3AR | |
| Cyclofenil SCHEMBL132246 | 0.89 | ESR1 (1.00) | ESR1PGRCHRM2ADORA3AR | |
| Cyclofenil SCHEMBL6340459 | 0.87 | ESR1 (0.97) | ESR1PGRCHRM2ADORA3AR | |
| Cyclofenil SCHEMBL9478209 | 0.86 | ESR1 (0.88) | ESR1PGRCHRM2ADORA3AR | |
| Cyclofenil SCHEMBL21045976 | 0.86 | ESR1 (0.94) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL384743 | 0.82 | GAA (0.57) | SRD5A2ELANEHSD17B10KLK1PRSS1 | |
| 4-(Acetate)Acetophenone SCHEMBL30735795 | 0.81 | SRD5A2 (0.55) | ESR1PGRCHRM2ADORA3AR | |
| SCHEMBL11489461 | 0.81 | GAA (0.55) | SRD5A2ELANEHSD17B10KLK1PRSS1 | |
| SCHEMBL29833587 | 0.76 | LMNA (0.69) | SRD5A2ELANEHSD17B10GAAKMT2A | |
| SCHEMBL29674918 | 0.75 | KMT2A (0.55) | SRD5A2ELANEHSD17B10GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-20210186932-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20200030259-A1 | Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms | REPROS THERAPEUTICS INC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-3515424-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | Repros Therapeutics Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3373967-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | Paracrine Therapeutics AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| EP-2819676-B1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2018058032-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | REPROS THERAPEUTICS INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20130165524-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8377991-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8372887-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120022167-A1 | Trans-Clomiphene for Metabolic Syndrome | REPROS THERAPEUTICS INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2211848-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | Repros Therapeutics Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7737185-B2 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2010054248-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME AND DIABETES MELLITUS TYPE 2 | REPROS THERAPEUTICS INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009051908-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099265-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20070249726-A1 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |